Mani Foroohar
Stock Analyst at Leerink Partners
(0.64)
# 4,184
Out of 4,662 analysts
944
Total ratings
44.6%
Success rate
-1.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABSI Absci | Initiated Coverage: Buy | $12 | $9.99 | +20.12% | 1 | Jun 4, 2026 | |
| RGNX REGENXBIO | Maintained: Buy | $17 | $12.02 | +41.43% | 64 | May 15, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $100 → $154 | $102.24 | +50.63% | 54 | May 15, 2026 | |
| ENGN enGene Therapeutics | Downgraded: Hold | $14 → $2 | $1.85 | +8.11% | 13 | May 8, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $27 → $35 | $13.28 | +163.55% | 52 | Apr 27, 2026 | |
| CAMP Camp4 Therapeutics | Maintained: Buy | $8 → $9 | $4.65 | +93.55% | 7 | Apr 2, 2026 | |
| RCKT Rocket Pharmaceuticals | Rated: Hold | $7 → $11 | $3.65 | +201.37% | 55 | Mar 27, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintained: Hold | n/a | $89.41 | - | 56 | Mar 26, 2026 | |
| MRNA Moderna | Maintained: Sell | $12 | $174.38 | -93.12% | 89 | Feb 11, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Hold | $370 → $351 | $242.61 | +44.68% | 67 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $68 → $100 | $60.80 | +64.47% | 67 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $370 → $86 | $83.95 | +2.44% | 76 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 → $2 | $0.7129 | +180.54% | 16 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $18 | $5.37 | +235.20% | 16 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 → $74 | $59.81 | +23.73% | 27 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $16.76 | - | 41 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.50 | - | 34 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $51 → $48 | $56.51 | -15.06% | 2 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $13.38 | +49.48% | 9 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $29.07 | - | 20 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 → $27 | $19.85 | n/a | 12 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $1.64 | n/a | 32 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $39.43 | n/a | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $3.25 | n/a | 20 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $4.17 | n/a | 31 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.2905 | n/a | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $21 | $4.92 | n/a | 15 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $7.15 | n/a | 1 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 → $5 | $5.42 | n/a | 24 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $6 | $6.13 | n/a | 17 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $37.04 | n/a | 7 | Oct 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $216 → $197 | $19.73 | n/a | 3 | Nov 6, 2020 |
Absci
Jun 4, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $9.99
Upside: +20.12%
REGENXBIO
May 15, 2026
Maintained: Buy
Price Target: $17
Current: $12.02
Upside: +41.43%
Mirum Pharmaceuticals
May 15, 2026
Maintained: Buy
Price Target: $100 → $154
Current: $102.24
Upside: +50.63%
enGene Therapeutics
May 8, 2026
Downgraded: Hold
Price Target: $14 → $2
Current: $1.85
Upside: +8.11%
Intellia Therapeutics
Apr 27, 2026
Reiterated: Buy
Price Target: $27 → $35
Current: $13.28
Upside: +163.55%
Camp4 Therapeutics
Apr 2, 2026
Maintained: Buy
Price Target: $8 → $9
Current: $4.65
Upside: +93.55%
Rocket Pharmaceuticals
Mar 27, 2026
Rated: Hold
Price Target: $7 → $11
Current: $3.65
Upside: +201.37%
Arrowhead Pharmaceuticals
Mar 26, 2026
Maintained: Hold
Price Target: n/a
Current: $89.41
Upside: -
Moderna
Feb 11, 2026
Maintained: Sell
Price Target: $12
Current: $174.38
Upside: -93.12%
Alnylam Pharmaceuticals
Dec 15, 2025
Maintained: Hold
Price Target: $370 → $351
Current: $242.61
Upside: +44.68%
Dec 15, 2025
Maintained: Buy
Price Target: $68 → $100
Current: $60.80
Upside: +64.47%
Dec 15, 2025
Maintained: Buy
Price Target: $370 → $86
Current: $83.95
Upside: +2.44%
Dec 15, 2025
Maintained: Buy
Price Target: $3 → $2
Current: $0.7129
Upside: +180.54%
Oct 21, 2025
Maintained: Buy
Price Target: $20 → $18
Current: $5.37
Upside: +235.20%
Oct 15, 2025
Maintained: Buy
Price Target: $56 → $74
Current: $59.81
Upside: +23.73%
Oct 15, 2025
Maintained: Buy
Price Target: n/a
Current: $16.76
Upside: -
Oct 15, 2025
Maintained: Hold
Price Target: n/a
Current: $3.50
Upside: -
Sep 25, 2025
Maintained: Buy
Price Target: $51 → $48
Current: $56.51
Upside: -15.06%
Sep 23, 2025
Reiterated: Buy
Price Target: $20
Current: $13.38
Upside: +49.48%
Sep 3, 2025
Maintained: Buy
Price Target: n/a
Current: $29.07
Upside: -
Aug 18, 2025
Maintained: Buy
Price Target: $32 → $27
Current: $19.85
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $3
Current: $1.64
Upside: n/a
Aug 12, 2025
Reiterated: Buy
Price Target: $70
Current: $39.43
Upside: n/a
Mar 6, 2025
Maintained: Hold
Price Target: $1
Current: $3.25
Upside: n/a
Aug 9, 2024
Maintained: Hold
Price Target: $1
Current: $4.17
Upside: n/a
Jul 15, 2024
Maintained: Buy
Price Target: n/a
Current: $0.2905
Upside: n/a
Nov 13, 2023
Maintained: Hold
Price Target: $21
Current: $4.92
Upside: n/a
Jun 8, 2023
Maintained: Sell
Price Target: n/a
Current: $7.15
Upside: n/a
May 23, 2023
Reiterated: Hold
Price Target: $6 → $5
Current: $5.42
Upside: n/a
Nov 14, 2022
Reiterated: Hold
Price Target: $5 → $6
Current: $6.13
Upside: n/a
Oct 19, 2021
Maintained: Hold
Price Target: n/a
Current: $37.04
Upside: n/a
Nov 6, 2020
Maintained: Buy
Price Target: $216 → $197
Current: $19.73
Upside: n/a